CR11098A - Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer - Google Patents

Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer

Info

Publication number
CR11098A
CR11098A CR11098A CR11098A CR11098A CR 11098 A CR11098 A CR 11098A CR 11098 A CR11098 A CR 11098A CR 11098 A CR11098 A CR 11098A CR 11098 A CR11098 A CR 11098A
Authority
CR
Costa Rica
Prior art keywords
compounds
pirimidina
pirido
ona
cancer treatment
Prior art date
Application number
CR11098A
Other languages
English (en)
Spanish (es)
Inventor
A Buhr Chris
Wang Longcheng
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CR11098A publication Critical patent/CR11098A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR11098A 2007-04-11 2009-11-09 Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer CR11098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11

Publications (1)

Publication Number Publication Date
CR11098A true CR11098A (es) 2010-01-27

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11098A CR11098A (es) 2007-04-11 2009-11-09 Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer

Country Status (25)

Country Link
US (2) US20100209340A1 (enExample)
EP (1) EP2142544B8 (enExample)
JP (1) JP2010523681A (enExample)
KR (1) KR20090130104A (enExample)
CN (1) CN101711249A (enExample)
AU (1) AU2008239596B2 (enExample)
BR (1) BRPI0810175A2 (enExample)
CA (1) CA2683820A1 (enExample)
CO (1) CO6241119A2 (enExample)
CR (1) CR11098A (enExample)
DO (1) DOP2009000242A (enExample)
EA (1) EA018964B1 (enExample)
EC (1) ECSP099722A (enExample)
ES (1) ES2425068T3 (enExample)
IL (1) IL201209A0 (enExample)
MA (1) MA31336B1 (enExample)
MX (1) MX2009010815A (enExample)
MY (1) MY150747A (enExample)
NI (1) NI200900183A (enExample)
NZ (1) NZ579945A (enExample)
SV (1) SV2009003389A (enExample)
TN (1) TN2009000389A1 (enExample)
UA (1) UA101315C2 (enExample)
WO (1) WO2008127712A1 (enExample)
ZA (1) ZA200906648B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
ATE514695T1 (de) 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
CA2683641C (en) 2007-04-10 2016-08-16 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
AU2008239655B2 (en) * 2007-04-11 2013-06-20 Exelixis, Inc. Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
PA8843901A1 (es) * 2008-09-30 2010-05-26 INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
MX2012007403A (es) * 2009-12-22 2012-09-12 Vertex Pharma Inhibidores de isoindolinona de fosfatidinositol 3-cinasa.
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
PE20141794A1 (es) 2011-11-01 2014-12-17 Exelixis Inc N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
ATE539752T1 (de) * 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
ATE514695T1 (de) * 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren

Also Published As

Publication number Publication date
EP2142544B1 (en) 2013-05-22
EA200970936A1 (ru) 2010-02-26
EP2142544B8 (en) 2013-07-03
JP2010523681A (ja) 2010-07-15
IL201209A0 (en) 2010-05-31
MA31336B1 (fr) 2010-04-01
AU2008239596A1 (en) 2008-10-23
NI200900183A (es) 2010-10-05
CA2683820A1 (en) 2008-10-23
HK1139941A1 (en) 2010-09-30
CO6241119A2 (es) 2011-01-20
TN2009000389A1 (en) 2010-12-31
MX2009010815A (es) 2009-10-29
EA018964B1 (ru) 2013-12-30
AU2008239596B2 (en) 2013-08-15
KR20090130104A (ko) 2009-12-17
ECSP099722A (es) 2009-12-28
MY150747A (en) 2014-02-28
WO2008127712A1 (en) 2008-10-23
US20100209340A1 (en) 2010-08-19
BRPI0810175A2 (pt) 2014-12-30
US20130343988A1 (en) 2013-12-26
DOP2009000242A (es) 2010-04-30
EP2142544A1 (en) 2010-01-13
NZ579945A (en) 2012-05-25
ZA200906648B (en) 2010-04-28
ES2425068T3 (es) 2013-10-11
CN101711249A (zh) 2010-05-19
SV2009003389A (es) 2010-04-27
UA101315C2 (ru) 2013-03-25

Similar Documents

Publication Publication Date Title
CR11098A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
UY31524A1 (es) Nuevos compuestos 010
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
NI201100108A (es) Nuevas pirazol - 4 - n - alcoxicarboxamidas como microbicidas.
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
ECSP109937A (es) Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt.
ECSP11011206A (es) Nuevos herbicidas.
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
ECSP109945A (es) Nuevos herbicidas
ECSP109942A (es) Nuevos herbicidas
BR112012029647A2 (pt) novos derivados de pirimidinas
NI200700319A (es) Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento.
ECSP099751A (es) Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazo[4,5-b]piridin-5-amina y su uso para el tratamiento del cáncer
AR067769A1 (es) Derivado de ditiazol para el tratamiento del cancer
CO6341625A2 (es) Derivados de indol como agentes anticáncer
ECSP11011133A (es) Nuevos herbicidas.